STOCK TITAN

AWH Applauds DEA on Decision to Move Cannabis from Schedule I to Schedule III

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Ascend Wellness Holdings, Inc. (AWH) supports the DEA's decision to move cannabis from Schedule I to Schedule III of the CSA, marking a significant step in cannabis reform. This change is expected to bring benefits like tax relief, improved access, funding opportunities, research advancements, and potential up-listing for AWH. The company looks forward to further developments and celebrates the decision's positive impact on stakeholders.

Ascend Wellness Holdings, Inc. (AWH) sostiene la decisione della DEA di trasferire la cannabis dalla Tabella I alla Tabella III della CSA, considerandola un passo importante nella riforma della cannabis. Questo cambiamento dovrebbe comportare vantaggi come agevolazioni fiscali, miglior accesso, opportunità di finanziamento, avanzamenti nella ricerca e la potenziale promozione in borsa per AWH. L'azienda attende con interesse ulteriori sviluppi e celebra l'impatto positivo della decisione sui suoi stakeholder.
Ascend Wellness Holdings, Inc. (AWH) apoya la decisión de la DEA de reclasificar el cannabis de la Lista I a la Lista III de la CSA, marcando un paso significativo en la reforma del cannabis. Se espera que este cambio traiga beneficios como alivio fiscal, mejor acceso, oportunidades de financiamiento, avances en investigación y una posible inclusión en listados superiores para AWH. La empresa espera con interés los desarrollos futuros y celebra el impacto positivo de la decisión en sus stakeholders.
Ascend Wellness Holdings, Inc. (AWH)는 대마초를 CSA의 일정 I에서 일정 III로 이동시키기로 한 DEA의 결정을 지지하며, 이는 대마초 개혁에서 중요한 단계를 표시합니다. 이 변경은 세금 감면, 개선된 접근성, 자금 조달 기회, 연구 개발 증진, 그리고 AWH의 잠재적인 상장 가능성과 같은 이점을 가져올 것으로 예상됩니다. 회사는 추가 발전을 기대하며 이 결정이 이해관계자들에게 미치는 긍정적인 영향을 축하합니다.
Ascend Wellness Holdings, Inc. (AWH) soutient la décision de la DEA de reclassifier le cannabis du Tableau I au Tableau III de la CSA, marquant une étape significative dans la réforme du cannabis. Ce changement devrait apporter des avantages tels que des allègements fiscaux, un accès amélioré, des opportunités de financement, des avancées dans la recherche et une possible réinscription en bourse pour AWH. L'entreprise attend avec impatience les développements futurs et célèbre l'impact positif de la décision sur les parties prenantes.
Ascend Wellness Holdings, Inc. (AWH) unterstützt die Entscheidung der DEA, Cannabis von Anhang I nach Anhang III des CSA zu verschieben, was einen bedeutenden Schritt in der Cannabisreform darstellt. Diese Änderung soll Vorteile wie Steuererleichterungen, verbesserten Zugang, Finanzierungsmöglichkeiten, Fortschritte in der Forschung und eine potenzielle Höherstufung für AWH bringen. Das Unternehmen freut sich auf weitere Entwicklungen und feiert die positive Auswirkung der Entscheidung auf die Stakeholder.
Positive
  • Support for DEA's decision to reschedule cannabis from Schedule I to Schedule III is a positive step for AWH and the industry.

  • Potential benefits include tax relief, improved access, funding opportunities, research avenues, and up-listing possibilities for AWH on major exchanges.

  • The decision is expected to bring positive impacts on stakeholders, including patients, customers, employees, license holders, and investors.

Negative
  • None.

NEW YORK, May 1, 2024 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH," "Ascend" or the "Company") (CSE: AAWH.U) (OTCQX: AAWH), a multi-state, vertically integrated cannabis operator, proudly announces support for the reports citing the Drug Enforcement Agency's ("DEA") decision to accept the recommendation of the U.S. Department of Health and Human Services ("HHS") to move cannabis from Schedule I to Schedule III of the Controlled Substances Act ("CSA").

John Hartmann, CEO of Ascend, provided a statement about the implications of this and what it means for the industry moving forward:

"The early reports citing that the DEA plans to agree with the HHS to reschedule cannabis from Schedule I to Schedule III mark a historic step forward from the Federal government on cannabis reform. This change is a pivotal move that opens a multitude of opportunities to cannabis operators like Ascend and is the most progressive act of cannabis reform that we have seen in decades. This favorable industry development could eliminate the 280e tax burden, improve customer and patient access, enhance access to funding, reduce the cost of capital, provide broader research avenues, and more. As we navigate this transformative landscape, Ascend eagerly anticipates exploring further potentials, including the possibility of up-listing to major exchanges. We look forward to seeing how this plays out in the coming months. We celebrate this unprecedented decision and eagerly anticipate the benefits it will bring to all industry stakeholders, including patients, customers, employees, license holders, investors, and others."

Ascend looks forward to the next steps in the rescheduling process before the rule is made final. Ascend employes approximately 2,400 people and operates 36 dispensaries and 7 cultivation facilities across Illinois, Maryland, Massachusetts, Michigan, Ohio, New Jersey, and Pennsylvania. To learn more, visit www.awholdings.com or read the 2023 Annual Report here.

About Ascend Wellness Holdings, Inc.

AWH is a vertically integrated operator with assets in Illinois, Maryland, Massachusetts, Michigan, Ohio, New Jersey, and Pennsylvania.  AWH owns and operates state-of-the-art cultivation facilities, growing award-winning strains and producing a curated selection of products for retail and wholesale customers. AWH produces and distributes its in-house Common Goods, Simply Herb, Ozone, Ozone Reserve, Tunnel Vision, and Royale branded products. For more information, visit www.awholdings.com.

Cautionary Note Regarding Forward-Looking Information

This news release includes forward-looking information and statements, which may include, but are not limited to, the plans, intentions, expectations, estimates, and beliefs of the Company. Words such as "expects", "continue", "will", "anticipates" and "intends" or similar expressions are intended to identify forward-looking information and statements. Without limiting the generality of the preceding statement, this news release contains forward-looking information and statements concerning the Company's current projections and expectations about future events and financial trends and the general stability of the economic and political environment.  We caution investors that any such forward-looking information and statements are based on certain assumptions and analysis made by the Company in light of the experience of the Company and its perception of historical trends, current conditions and expected future developments, and other factors management believes are appropriate.

Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Such factors include, among others, the risks and uncertainties identified in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and in the Company's other reports and filings with the applicable Canadian securities regulators on its profile on SEDAR+ at www.sedarplus.ca and with the SEC on its profile on EDGAR at www.sec.gov. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information or statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward-looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws. The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Cision View original content:https://www.prnewswire.com/news-releases/awh-applauds-dea-on-decision-to-move-cannabis-from-schedule-i-to-schedule-iii-302132470.html

SOURCE Ascend Wellness Holdings, Inc.

FAQ

What is the significance of the DEA's decision for AWH?

The DEA's decision to move cannabis from Schedule I to Schedule III is significant for AWH as it opens up various opportunities for the company, such as tax relief, increased access, funding options, research advancements, and potential up-listing on major exchanges.

How many dispensaries and cultivation facilities does Ascend operate?

Ascend operates 36 dispensaries and 7 cultivation facilities across several states, including Illinois, Maryland, Massachusetts, Michigan, Ohio, New Jersey, and Pennsylvania.

Where can I find more information about Ascend Wellness Holdings, Inc.?

More information about AWH can be found on their website www.awholdings.com or by reading their 2023 Annual Report.

ASCEND WELLNESS HOLDNGS A

OTC:AAWH

AAWH Rankings

AAWH Latest News

AAWH Stock Data

99.68M
136.31M
30.29%
8.55%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
New York